In this review, we consider recent advances in the discovery and development of antiviral agents for respiratory syncytial virus (RSV) infections. A background to the various manifestations of human RSV infection and current treatments is provided. The technical, clinical and commercial issues surrounding the development of such antiviral agents are discussed.
Get full access to this article
View all access options for this article.
References
1.
StoreyS. Respiratory syncytial virus market. Nat Rev Drug Discov2010; 9:15–16.
HallCBGeimanJMBiggarRKotokDIHoganPMDouglasGRJr. Respiratory syncytial virus infections within families. N Engl J Med1976; 294:414–419.
4.
SimoesEACarbonell-EstranyX. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatr Infect Dis J2003; 22Suppl 2: S13–S18.
5.
JohnsonKMBloomHHMufsonMAChanockRM. Natural reinfection of adults by respiratory syncytial virus. Possible relation to mild upper respiratory disease. N Engl J Med1962; 267:68–72.
6.
BowdenRA. Respiratory virus infections after marrow transplant: The Fred Hutchinson Cancer Research Center experience. Am J Med1997; 102Suppl 1:27–30.
7.
StensballeLGDevasundaramJKSimoesEA. Respiratory syncytial virus epidemics: The ups and downs of a seasonal virus. Pediatr Infect Dis J2003; 22Suppl 2:S21–S32.
8.
LeaderSKohlhaseK. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr2003; 143Suppl 5:S127–S132.
9.
GlezenWPTaberLHFrankALKaselJA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child1986; 140:543–546.
10.
BockovaJO'BrienKLOskiJ. Respiratory syncytial virus infection in Navajo and White Mountain Apache children. Pediatrics2002; 110:e20.
11.
NairHNokesDJGessnerBD. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet2010; 375:1545–1555.
12.
TregoningJSSchwarzeJ. Respiratory viral infections in infants: Causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev2010; 23:74–98.
13.
KapikianAZMitchellRHChanockRMShvedoffRAStewartCE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol1969; 89:405–421.
14.
GroothuisJRSimoesEA. Immunoprophylaxis and immunotherapy: Role in the prevention and treatment of repiratory syncytial virus. Int J Antimicrob Agents1993; 2:97–103.
15.
WrightPFKarronRABelsheRB. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine2007; 25:7372–7378.
16.
GroothuisJRHoopesJMJessieVG. Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention. Adv Ther2011; 28:91–109.
17.
HabibiMSPatelSOpenshawP. Hot topics in the prevention of respiratory syncytial virus disease. Expert Rev Vaccines2011; 10:291–293.
GroothuisJRSimoesEALevinMJ. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med1993; 329:1524–1530.
20.
WeismanLE. Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: Infants with predisposing conditions. Pediatr Infect Dis J2003; 22Suppl 2: S33–S37.
21.
PollackPGroothuisJR, Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV. J infect Chemother2002; 8: 201–206.
The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics1998; 102:531–537.
24.
FeltesTFCabalkaAKMeissnerHC. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically signif-cant congenital heart disease. J Pediatr2003; 143:532–540.
25.
StewartDL. Studies recommending palivizumab restriction have serious defciencies. J Manag Care Pharm2010; 16:509–511.
26.
MejíasAChavez-BuenoSRiosAM. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: Time versus potency. Antimicrob Agents Chemother2005; 49:4700–4707.
27.
Carbonell-EstranyXSimoesEADaganR. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: A noninferiority trial. Pediatrics2010; 125:e35–e51.
28.
PowellKLAlberDG. Development of antivirals against respiratory syncytial virus. In CaneP (Editor). Respiratory syncytial virus. Perspectives in medical virology. Amsterdam: Elsevier BV Publishers2006; pp. 279–298.
29.
YuKLSinNCivielloRL. Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailabil-ity. Bioorg Med Chem Lett2007; 17:895–901.
30.
WangXACianciCWYuKL. Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity. Bioorg Med Chem Lett2007; 17:4592–4598.
31.
SinNVenablesBLCombrinkKD. Respiratory syncytial virus fusion inhibitors. Part 7: Structure–activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett2009; 19:4857–4862.
32.
CombrinkKDGulgezeHBThuringJW. Respiratory syncytial virus fusion inhibitors. Part 6: An examination of the effect of structural variation of the benzimidazol-2-one heterocycle moiety. Bioorg Med Chem Lett2007; 17:4784–4790.
33.
BladeHCarronEAJacksonHM, inventors. AstraZeneca UK Ltd., Arrow Therapeutics Ltd, assignee. Ben-zimidazole derivatives as RSV protein inhibitors and their preparation, pharmaceutical compositions and use in the treatment of respiratory syncytial virus infections. United States patent WO/2010/103306. 2010 September 16.
34.
BonfantiJMMeyerCDoubletC. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholino-propylaminobenzimidazole derivative (TMC353121). J Med Chem2008; 51:875–896.
35.
RoymansDDe BondtHLArnoultE. Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci U S A2010; 107:308–313.
36.
RouanMCGeversTRoymansD. Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model. Antimicrob Agents Chemother2010; 54:4534–4539.
37.
LundinABergstromTBendriouaLKannNAdamiakBTrybalaE. Two novel fusion inhibitors of human respiratory syncytial virus. Antiviral Res2010; 88:317–324.
38.
DouglasJLPanisMLHoE. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J Virol2003; 77:5054–5064.
39.
CookR. MDT-637, a novel antiviral treatment for respiratory syncytial virus infection. 7th International Respiratory Syncytial Virus (RSV) Symposium. 2–5 December 2010, Rotterdam, the Netherlands. Abstract 0.04.
40.
QuraishiOSStoddardCABlackP, inventors; Conjuchem Biotechnologies Inc., assignee. Long lasting modified antifu-sogenic peptide for preventing HIV infection. United States patent WO/2008/144J90. 2008 November 27.
41.
PeeplesMEKennedyMRayW, inventors; Nationwide Children's Hospital, Inc., assignee. Methods and compositions relating to viral fusion proteins. United States patent 20100261155. 2010 October 14.
42.
ParkMMatsuuraHLambRA. A fluorescence polarization assay using an engineered human respiratory syncytial virus F protein as a direct screening platform. Anal Biochem2001; 409:195–201.
43.
CorteseRPessiA, inventors. Cormus SRL, assignee. Inhibitors of viral fusion an uses thereof. Italy patent WO/2010/089129. 2010 August 12.
44.
PrudomCEKarlssonLMillerSWilliamsJCroweJJr.WrightD. Structure activity relationship of heptad repeat peptide truncates that prevent viral fusion. 60th Southeast Regional Meeting of the American Chemical Society. 12–15 November 2008, Nashville, TN, USA. Abstract 17.
45.
HarrisonRSShepherdNEHoangHN. Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potency. Proc Natl Acad Sci U S A2010; 107:11686–11691.
46.
KimuraKMoriSTomitaK. Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo. Antiviral Res2000; 47:41–51.
47.
KimuraKIshiokaKHashimotoK. Isolation and characterization of NMSO3-resistant mutants of respiratory syncytial virus. Antiviral Res2004; 61:165–171.
48.
MalykhinaOYednakMACollinsPLOlivoPDPeeplesME. A respiratory syncytial virus replicon that is noncyto-toxic and capable of long-term foreign gene expression. J Virol2011; 85:4792–4801.
49.
CarterMCAlberDGBaxterRC. 1,4-Benzodiaz-epines as inhibitors of respiratory syncytial virus. J Med Chem2006; 49:2311–2319.
50.
ChapmanJAbbottEAlberDG. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother2007; 51:3346–3353.
51.
ZhangLPeeplesMEBoucherRCCollinsPLPicklesRJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol2002; 76:5654–5666.
52.
MartyFMChemalyRFLiakopoulouEDentJCPowellKL. Randomised, placebo-controlled study to evaluate the safety and efficacy of RSV604 in adults with Respiratory Syncytial Virus (RSV) infection following stem sell transplantation. IX International symposium on Respiratory Virus Infection. 3–6 March 2007, Hong Kong SAR, China.
53.
TawarRGDuquerroySVonrheinC. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science2009; 326:1279–1283.
54.
SidwellRWHuffmanJHKhareGPAllenLBWitkowskiJTRobinsRK. Broad-spectrum antiviral activity of vira-zole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science1972; 177:705–706.
55.
TamRCLauJYHongZ. Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother2001; 12:261–272.
56.
DeVincenzoJLambkin-WilliamsRWilkinsonT. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A2010; 107:8800–8805.
57.
LinCCPhilipsLXuCYehLT. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J Clin Pharmacol2004; 44:265–275.
58.
ArnoldRKönigK. Peroxisome proliferator-activated receptor-gamma agonists inhibit the replication of respiratory syncytial virus (RSV) in human lung epithelial cells. Virology2006; 350:335–346.
59.
OtakeKOmotoSYamamotoT. HIV-1 Nef protein in the nucleus influences adipogenesis as well as viral transcription through the peroxisome proliferator-activated receptors. AIDS2004; 18:189–198.
60.
SudoKMiyazakiYKojimaN. YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. Antiviral Res2005; 65:125–131.
61.
MackmanRLSperandioDYangH, inventors; Gilead Sciences Inc., Preparation of thienobenzazepine derivatives as RSV inhibitors and useful in the treatment of RSV infection. United States patent WO/2011/00J842. 2011 January 13.
62.
MasonSWLawetzCGaudetteY. Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor. Nucleic Acids Res2004; 32:4758–4767.
63.
LiuzziMMasonSWCartierM. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase. J Virol2005; 79:13105–13115.
64.
OlivoPDBuscherBADyallJ, inventors; Apath LLC, assignee. 4-Aminoquinoline compounds for treating virus-related conditions. United States patent WO/2006/093J18. 2006 September 8.
65.
LaiSHSteinDAGuerreo-PlataA. Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice. Mol Ther2008; 16:1120–1128.
66.
BonaviaAFrantiMPusateri KeaneyE. Organic synthesis toward small-molecule probes and drugs special feature: Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV). Proc Natl Acad Sci U S A2011; 108:6739–6744.
67.
ShimMSKwonYJ. Efficient and targeted delivery of siRNA in vivo. FEBS J2010; 277:4814–4827.
68.
BitkoVMusiyenkoAShulyayevaOBarikS. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med2005; 11:50–55.
69.
AlvarezRElbashirSBorlandT. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother2009; 53:3952–3962.
70.
BannisterRRodriguesDMurrayEJLaxtonCWestbyMBrightH. Use of a highly sensitive strand-specific quantitative PCR to identify abortive replication in the mouse model of respiratory syncytial virus disease. Virol J2010; 7:250–261.
71.
ZamoraMRBudevMRolfeM. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med2011; 183:531–538.
72.
HemidaMGYeXThairSYangD. Exploiting the therapeutic potential of microRNAs in viral diseases: Expectations and limitations. Mol Diagn Ther2010; 14:271–282.
73.
LeeFEWalshEEFalseyARBettsRFTreanorJJ. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res2004; 63:191–196.
74.
DeVincenzoJPWilkinsonTVaishnawA. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med2010; 182:1305–1314.
75.
BerminghamAHenricksonKHaydenFZambonM. VII International Symposium on Respiratory Viral Infections. Antivir Ther2007; 12:671–693.
76.
ShahJNChemalyRF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood2011; 117:2755–2763.
